Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Genetec Corp. (4492:JPX), powered by AI.
Genetec Corp. is currently trading at ¥375. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Genetec Corp. on Alpha Lenz.
Genetec Corp.'s P/E ratio is 10.2.
“Genetec Corp. trades at a P/E of 10.2 (undervalued) with strong ROE of 18.2%. 3Y revenue CAGR of 20.2% highlights clear growth momentum.”
Ask for details →Genetec Corp. is a prominent player in the biotechnology industry, focusing on the development, production, and commercialization of biopharmaceutical products. Genetec’s primary function is to innovate in the field of medical therapies, leveraging cutting-edge biotechnology to address chronic and life-threatening diseases. The company is heavily involved in research and development, driving advancements in areas such as cancer treatment, immunology, and genetic disorders. Its products are vital in catering to the pharmaceutical needs of healthcare facilities worldwide, impacting sectors such as healthcare, pharmaceuticals, and biotechnology research. As a significant entity in the financial market, Genetec Corp. contributes to the biotech sector's growth, influencing global healthcare trends. The company's efforts in pioneering drug innovations and clinical advancements play a critical role in improving patient outcomes and propelling medical science forward.
“Genetec Corp. trades at a P/E of 10.2 (undervalued) with strong ROE of 18.2%. 3Y revenue CAGR of 20.2% highlights clear growth momentum.”
Ask for details →Genetec Corp. (ticker: 4492) is a company listed on JPX in the Technology sector (Software - Application). It has approximately 619 employees. Market cap is $4.3B.
The current price is 375 with a P/E ratio of 10.19x and P/B of 1.78x.
ROE is 18.24% and operating margin is 8.54%. Annual revenue is $8.1B.